For both inherited conditions, immediate detection is critical to advancing a positive outcome. For SMA, disease modifying therapies exist to stop progression of disease, and for SCID, immunoglobulin ...

Revvity, Inc. RVTY announced the launch of its latest breakthrough — the EONIS Q system. This innovative platform marks a significant leap in the molecular testing landscape for spinal muscular ...

The Eonis™ Q system from Revvity is an innovative dry PCR workflow that simplifies and streamlines molecular testing for SMA and SCID. It comprises the compact Eonis™ Q96 instrument, stable and ...

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc., announced the launch of its EONIS™ Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt ...